Objective  To assess the relationship between LncRNA MIR210HG and the clinicopathological characteristics of patients with bladder cancer and explore its impact on the malignant biological behavior of bladder cancer cells through a series of experiments.

  Methods   The clinicopathological data from 70 patients with bladder cancer at The Fourth Hospital of Hebei Medical University was collected between June and December, 2022. The expression of LncRNA MIR210HG was detected using real-time fluorescence quantitative PCR (RT-PCR), and its correlation with clinicopathological characteristics was analyzed. The effects of LncRNA MIR210HG on the biological behavior of bladder cancer cells were assessed through MTS, clone formation, scratch, and Transwell invasion experiments.

  Results   LncRNA MIR210HG expression was significantly higher in bladder cancer tissues and T24, 5637, and SW780 bladder cancer cells (P<0.05). In bladder cancer tissues, the relative expression of LncRNA MIR210HG in cases with lymph node metastasis (3.847±1.047) was significantly higher (P<0.05) in comparison to those without lymph node metastasis (2.915±0.904). Similarly, tissues with myometrial invasion (3.353±1.032) exhibited significantly higher (P<0.05) LncRNA MIR210HG expression than those without myometrial invasion (2.822±0.872). Interfering with LncRNA MIR210HG expression inhibited the proliferation, migration, and invasion of bladder cancer (all P<0.05), while overexpression significantly enhanced these processes (all P<0.05).

  Conclusions   LncRNA MIR210HG is highly expressed in bladder cancer tissues and promotes myometrial invasion and lymphatic metastasis. These findings provide valuable insights for clinical treatment strategies and may improve overall survival rates for patients with bladder cancer.